Gestern wurden ja die Zahlen des 4. Quartals 2014
und der gesamte Jahresabschluss von OncoGenex veröffentlicht
bzw. vorgestellt.
Die Zahlen waren deutlich über den Schätzungen.
Jahresumsatz: 27,1 Mio.
Ist eine Marktkapitalisierung von 48,3 Mio. von OncoGenex dann#
nicht deutlich zu gering ?
Die Verluste sind auch niedriger als erwartet !
4. Quartal: 0,26 Cent je Aktie, 0,30 Cent je Aktie wurden erwartet,
also alles im allen doch sehr positiv.
Ich muss mir noch die Zukunftsaussichten, welche in einer Telefon-
konferenz gestern Abend vorgestellt wurden, noch genau druchlesen.
Tom.
Was habt Ihr für eine Meinung dazu ?
Quelle:
http://www.nasdaq.com/press-release/...d-year-end-2014-20150326-00857Financial Update and Results
Revenue for the fourth quarter and year ended December 31, 2014 was $5.7 million and $27.1 million, respectively. This compares with $8.6 million and $29.9 million, respectively, in the same periods in 2013. Revenue earned in 2014 consists of reimbursable clinical trial, manufacturing and preclinical costs incurred by OncoGenex under the collaboration agreement with Teva.
Total operating expenses for the fourth quarter and year ended December 31, 2014 were $12.3 million and $56.6 million, respectively.
Net loss for the fourth quarter and year ended December 31, 2014 was $5.7 million, and $26.2 million, respectively.
In Feburary 2015, the company announced the execution of new lease agreements enabling the relocation of its Bothell, Washington headquarters, yielding significant savings through 2017.
The company had $47.1 million in cash, cash equivalents and short-term investments as of December 31, 2014, compared to $39.2 million as of December 31, 2013.
Based on current expectations, the company believes its capital resources as of December 31, 2014 will be sufficient to fund its currently planned operations into the third quarter of 2016, and through:
Results from the Phase 3 AFFINITY trial expected in late 2015/early 2016;
Completion of patient enrollment in the Borealis-2 trial expected in late 2015;
Results from the Rainier trial expected in late 2015/early 2016; and
Results from the Spruce trial expected by mid-2016.
Upon completion of the termination agreement with Teva, we expect that we would receive a payment of approximately $27 million, subject to certain adjustments, which we believe, together with our current cash and cash equivalents, would be sufficient to complete the milestones listed above as well as a modified second futility analysis of the ENSPIRIT trial. Additional capital will be required to fund completion of ENSPIRIT beyond the second futility analysis.
At March 26, 2015, OncoGenex had 22,679,086 shares outstanding.
Read more:
http://www.nasdaq.com/press-release/...4-20150326-00857#ixzz3VaCmsryO
Thread abonnieren
